EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 22018D1769
Decision of the EEA Joint Committee No 35/2017 of 3 February 2017 amending Annex IX (Financial services) to the EEA Agreement [2018/1769]
Decision of the EEA Joint Committee No 35/2017 of 3 February 2017 amending Annex IX (Financial services) to the EEA Agreement [2018/1769]
Decision of the EEA Joint Committee No 35/2017 of 3 February 2017 amending Annex IX (Financial services) to the EEA Agreement [2018/1769]
OJ L 297, 22/11/2018, p. 44–46
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
In force
|
22.11.2018 |
EN |
Official Journal of the European Union |
L 297/44 |
DECISION OF THE EEA JOINT COMMITTEE
No 35/2017
of 3 February 2017
amending Annex IX (Financial services) to the EEA Agreement [2018/1769]
THE EEA JOINT COMMITTEE,
Having regard to the Agreement on the European Economic Area (‘the EEA Agreement’), and in particular Article 98 thereof,
Whereas:
|
(1) |
Commission Implementing Decision 2014/752/EU of 30 October 2014 on the equivalence of the regulatory framework of Japan for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (1) is to be incorporated into the EEA Agreement. |
|
(2) |
Commission Implementing Decision 2014/753/EU of 30 October 2014 on the equivalence of the regulatory framework of Singapore for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (2) is to be incorporated into the EEA Agreement. |
|
(3) |
Commission Implementing Decision 2014/754/EU of 30 October 2014 on the equivalence of the regulatory framework of Hong Kong for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (3) is to be incorporated into the EEA Agreement. |
|
(4) |
Commission Implementing Decision 2014/755/EU of 30 October 2014 on the equivalence of the regulatory framework of Australia for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (4) is to be incorporated into the EEA Agreement. |
|
(5) |
Commission Implementing Decision (EU) 2015/2038 of 13 November 2015 on the equivalence of the regulatory framework of the Republic of Korea for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (5) is to be incorporated into the EEA Agreement. |
|
(6) |
Commission Implementing Decision (EU) 2015/2039 of 13 November 2015 on the equivalence of the regulatory framework of South Africa for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (6) is to be incorporated into the EEA Agreement. |
|
(7) |
Commission Implementing Decision (EU) 2015/2040 of 13 November 2015 on the equivalence of the regulatory framework of certain provinces of Canada for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (7) is to be incorporated into the EEA Agreement. |
|
(8) |
Commission Implementing Decision (EU) 2015/2041 of 13 November 2015 on the equivalence of the regulatory framework of Mexico for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (8) is to be incorporated into the EEA Agreement. |
|
(9) |
Commission Implementing Decision (EU) 2015/2042 of 13 November 2015 on the equivalence of the regulatory framework of Switzerland for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (9) is to be incorporated into the EEA Agreement. |
|
(10) |
Annex IX to the EEA Agreement should therefore be amended accordingly, |
HAS ADOPTED THIS DECISION:
Article 1
The following points are inserted after point 31bc (Regulation (EU) No 648/2012 of the European Parliament and of the Council) of Annex IX to the EEA Agreement:
|
‘31bcaa. |
32014 D 0752: Commission Implementing Decision 2014/752/EU of 30 October 2014 on the equivalence of the regulatory framework of Japan for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (OJ L 311, 31.10.2014, p. 55). |
|
31bcab. |
32014 D 0753: Commission Implementing Decision 2014/753/EU of 30 October 2014 on the equivalence of the regulatory framework of Singapore for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (OJ L 311, 31.10.2014, p. 58). |
|
31bcac. |
32014 D 0754: Commission Implementing Decision 2014/754/EU of 30 October 2014 on the equivalence of the regulatory framework of Hong Kong for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (OJ L 311, 31.10.2014, p. 62). |
|
31bcad. |
32014 D 0755: Commission Implementing Decision 2014/755/EU of 30 October 2014 on the equivalence of the regulatory framework of Australia for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (OJ L 311, 31.10.2014, p. 66). |
|
31bcae. |
32015 D 2038: Commission Implementing Decision (EU) 2015/2038 of 13 November 2015 on the equivalence of the regulatory framework of the Republic of Korea for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (OJ L 298, 14.11.2015, p. 25). |
|
31bcaf. |
32015 D 2039: Commission Implementing Decision (EU) 2015/2039 of 13 November 2015 on the equivalence of the regulatory framework of South Africa for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (OJ L 298, 14.11.2015, p. 29). |
|
31bcag. |
32015 D 2040: Commission Implementing Decision (EU) 2015/2040 of 13 November 2015 on the equivalence of the regulatory framework of certain provinces of Canada for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (OJ L 298, 14.11.2015, p. 32). |
|
31bcah. |
32015 D 2041: Commission Implementing Decision (EU) 2015/2041 of 13 November 2015 on the equivalence of the regulatory framework of Mexico for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (OJ L 298, 14.11.2015, p. 38). |
|
31bcai. |
32015 D 2042: Commission Implementing Decision (EU) 2015/2042 of 13 November 2015 on the equivalence of the regulatory framework of Switzerland for central counterparties to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories (OJ L 298, 14.11.2015, p. 42).’ |
Article 2
The texts of Implementing Decisions 2014/752/EU, 2014/753/EU, 2014/754/EU, 2014/755/EU, (EU) 2015/2038, (EU) 2015/2039, (EU) 2015/2040, (EU) 2015/2041 and (EU) 2015/2042 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic.
Article 3
This Decision shall enter into force on 4 February 2017, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*1), or on the day of the entry into force of Decision of the EEA Joint Committee No 206/2016 of 30 September 2016 (10), whichever is the later.
Article 4
This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union.
Done at Brussels, 3 February 2017.
For the EEA Joint Committee
The President
Claude MAERTEN
(1) OJ L 311, 31.10.2014, p. 55.
(2) OJ L 311, 31.10.2014, p. 58.
(3) OJ L 311, 31.10.2014, p. 62.
(4) OJ L 311, 31.10.2014, p. 66.
(5) OJ L 298, 14.11.2015, p. 25.
(6) OJ L 298, 14.11.2015, p. 29.
(7) OJ L 298, 14.11.2015, p. 32.
(8) OJ L 298, 14.11.2015, p. 38.
(9) OJ L 298, 14.11.2015, p. 42.
(*1) No constitutional requirements indicated.